Karin Reif

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/234675/publications.pdf

Version: 2024-02-01

186265 330143 4,003 37 28 37 citations h-index g-index papers 37 37 37 4641 citing authors docs citations times ranked all docs

#	Article	IF	Citations
1	Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position. Nature, 2002, 416, 94-99.	27.8	506
2	Phosphatidylinositol 3-Kinase Couples the Interleukin-2 Receptor to the Cell Cycle Regulator E2F. Immunity, 1997, 7, 679-689.	14.3	383
3	Follicular stromal cells and lymphocyte homing to follicles. Immunological Reviews, 2000, 176, 181-193.	6.0	365
4	Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis. Nature Chemical Biology, 2011, 7, 41-50.	8.0	302
5	Phosphatidylinositol 3-kinase signals activate a selective subset of Rac/Rho-dependent effector pathways. Current Biology, 1996, 6, 1445-1455.	3.9	257
6	Cutting Edge: Differential Roles for Phosphoinositide 3-Kinases, p $110\hat{l}^3$ and p $110\hat{l}^3$, in Lymphocyte Chemotaxis and Homing. Journal of Immunology, 2004, 173, 2236-2240.	0.8	217
7	Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. Journal of Medicinal Chemistry, 2018, 61, 2227-2245.	6.4	177
8	Phosphatidylinositol 3-Kinase Links the Interleukin-2 Receptor to Protein Kinase B and p70 S6 Kinase. Journal of Biological Chemistry, 1997, 272, 14426-14433.	3.4	161
9	The regulation and function of p21ras during T-cell activation and growth. Trends in Immunology, 1995, 16, 159-164.	7.5	155
10	RGS Molecule Expression in Murine B Lymphocytes and Ability to Down-Regulate Chemotaxis to Lymphoid Chemokines. Journal of Immunology, 2000, 164, 4720-4729.	0.8	135
11	Ligation of the T cell co-stimulatory receptor CD28 activates the serine-threonine protein kinase protein kinase protein kinase B. European Journal of Immunology, 1997, 27, 2495-2501.	2.9	109
12	Protection of CD95-mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B. European Journal of Immunology, 1998, 28, 57-69.	2.9	103
13	The protein interactions of the immunoglobulin receptor family tyrosine-based activation motifs present in the T cell receptor $\hat{\bf l}^q$ subunits and the CD3 $\hat{\bf l}^3$, $\hat{\bf l}'$ and $\hat{\bf l}\mu$ chains. European Journal of Immunology, 1996, 26, 1063-1068.	2.9	98
14	Antiarthritis Effect of a Novel Bruton's Tyrosine Kinase (BTK) Inhibitor in Rat Collagen-Induced Arthritis and Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling: Relationships between Inhibition of BTK Phosphorylation and Efficacy. Journal of Pharmacology and Experimental Therapeutics, 2011, 338, 154-163.	2.5	85
15	The CDM protein DOCK2 in lymphocyte migration. Trends in Cell Biology, 2002, 12, 368-373.	7.9	83
16	Networking Rho Family GTPases in Lymphocytes. Immunity, 1998, 8, 395-401.	14.3	80
17	CD200R1 Agonist Attenuates Mechanisms of Chronic Disease in a Murine Model of Multiple Sclerosis. Journal of Neuroscience, 2010, 30, 2025-2038.	3.6	71
18	Divergent regulation of phosphatidylinositol 3-kinase P85 alpha and P85 beta isoforms upon T cell activation. Journal of Biological Chemistry, 1993, 268, 10780-8.	3.4	68

#	Article	IF	CITATIONS
19	SH3 domains of the adapter molecule Grb2 complex with two proteins in T cells: the guanine nucleotide exchange protein Sos and a 75-kDa protein that is a substrate for T cell antigen receptor-activated tyrosine kinases. Journal of Biological Chemistry, 1994, 269, 14081-7.	3.4	67
20	Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell–associated damage in IFNα-driven lupus nephritis. JCl Insight, 2017, 2, e90111.	5.0	65
21	Discovery of Novel PI3-Kinase δSpecific Inhibitors for the Treatment of Rheumatoid Arthritis: Taming CYP3A4 Time-Dependent Inhibition. Journal of Medicinal Chemistry, 2012, 55, 5887-5900.	6.4	61
22	A negative role for phosphoinositide 3-kinase in T-cell antigen receptor function. Current Biology, 1997, 7, 285-293.	3.9	56
23	Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1333-1337.	2.2	55
24	Potent and selective inhibitors of PI3K \hat{l} : Obtaining isoform selectivity from the affinity pocket and tryptophan shelf. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4296-4302.	2.2	48
25	Regulation of the Adapter Molecule Grb2 by the FclµR1 in the Mast Cell Line RBL2H3. Journal of Biological Chemistry, 1995, 270, 9500-9506.	3.4	46
26	p21ras initiates Rac-1 but not phosphatidyl inositol 3 kinase/PKB, mediated signaling pathways in T lymphocytes. Oncogene, 1998, 17, 1731-1738.	5.9	38
27	Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 575-579.	2.2	34
28	Automated Affinity Capture and On-Tip Digestion to Accurately Quantitate <i>in Vivo</i> Deamidation of Therapeutic Antibodies. Analytical Chemistry, 2016, 88, 11521-11526.	6.5	29
29	Identification of GNE-293, a potent and selective PI3K $\hat{\Gamma}$ inhibitor: Navigating in vitro genotoxicity while improving potency and selectivity. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4953-4959.	2.2	27
30	Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties. ACS Medicinal Chemistry Letters, 2017, 8, 608-613.	2.8	26
31	Depletion of major pathogenic cells in asthma by targeting CRTh2. JCI Insight, 2016, 1, e86689.	5.0	26
32	Bruton's Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in Rats. Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 226-238.	2.5	19
33	Regulation of PtdIns-3-kinase and the guanine nucleotide binding proteins p21ras during signal transduction by the T cell antigen receptor and the interleukin-2 receptor. Seminars in Immunology, 1993, 5, 319-326.	5 . 6	13
34	Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity. ACS Medicinal Chemistry Letters, 2020, 11, 1588-1597.	2.8	12
35	In vitro mutagenesis of a xylanase from the extreme thermophile Caldocellum saccharolyticum. Applied Microbiology and Biotechnology, 1992, 36, 503-6.	3.6	10
36	45 Activation of the PI3K Effector Protein Kinase B Following Ligation of CD28 or Fas. Biochemical Society Transactions, 1997, 25, S589-S589.	3.4	9

#	Article	IF	CITATIONS
37	Preclinical Safety Profile of a Depleting Antibody against CRTh2 for Asthma: Well Tolerated Despite Unexpected CRTh2 Expression on Vascular Pericytes in the Central Nervous System and Gastric Mucosa. Toxicological Sciences, 2016, 152, 72-84.	3.1	7